IgA Nephropathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Description
IgA Nephropathy Market Outlook
Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
IgA Nephropathy Overview
IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide and is characterized by immune complex deposition in the kidneys, leading to progressive renal damage. The disease is driven by abnormal glycosylation of O-linked glycans in the hinge region of IgA1, resulting in elevated levels of galactose-deficient IgA1 (Gd-IgA1) in circulation. These abnormal IgA1 molecules are recognized by glycan-specific IgA and IgG autoantibodies, forming immune complexes that deposit in the glomeruli and trigger inflammation.
IgA, a key antibody in mucosal immunity, exists primarily as IgA1 and IgA2, with secretory IgA produced by mucosal-associated lymphoid tissues in polymeric form. In IgAN, this immune dysregulation leads to sustained kidney injury.
Clinically, IgAN follows a slow but progressive course, with approximately 30–40% of patients progressing to end-stage renal disease (ESRD) within 20–30 years. The disease may occur as sporadic (90–95%) or familial (5–10%) forms, with familial cases often associated with a more severe prognosis and faster progression to renal failure.
Key Highlights
IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)
Market Overview
Germany market projected to grow from $116M to $950M (>20% CAGR)
Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Thelansis’s “IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
IgA Nephropathy Overview
IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide and is characterized by immune complex deposition in the kidneys, leading to progressive renal damage. The disease is driven by abnormal glycosylation of O-linked glycans in the hinge region of IgA1, resulting in elevated levels of galactose-deficient IgA1 (Gd-IgA1) in circulation. These abnormal IgA1 molecules are recognized by glycan-specific IgA and IgG autoantibodies, forming immune complexes that deposit in the glomeruli and trigger inflammation.
IgA, a key antibody in mucosal immunity, exists primarily as IgA1 and IgA2, with secretory IgA produced by mucosal-associated lymphoid tissues in polymeric form. In IgAN, this immune dysregulation leads to sustained kidney injury.
Clinically, IgAN follows a slow but progressive course, with approximately 30–40% of patients progressing to end-stage renal disease (ESRD) within 20–30 years. The disease may occur as sporadic (90–95%) or familial (5–10%) forms, with familial cases often associated with a more severe prognosis and faster progression to renal failure.
Key Highlights
IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)
Market Overview
Germany market projected to grow from $116M to $950M (>20% CAGR)
Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
In-depth interviews with leading KOLs and payers
Physician surveys
RWE analysis for claims and EHR datasets
Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Key business questions answered:
How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
What is the 10-year market outlook for sales and patient share?
Which events will have the greatest impact on the market’s trajectory?
What insights do interviewed experts provide on current and emerging treatments?
Which pipeline products show the most promise, and what is their potential for launch and future positioning?
What are the key unmet needs and KOL expectations for target profiles?
What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
and more…
Country covered:G8 Markets
United States
EU5
France
Germany
Italy
Spain
U.K.
Japan
China
Table of Contents
154 Pages
- 1. Key Findings and Analyst Commentary
- 1.1 Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.
- 2. Disease Context
- 2.1 Disease definition, classification, etiology and pathophysiology, drug targets, etc.
- 3. Epidemiology
- 3.1 Key takeaways
- 3.2 Incidence / Prevalence
- 3.3 Diagnosed and Drug-Treated populations
- 3.4 Comorbidities
- 3.5 Other relevant patient segments
- 4. Market Size and Forecast
- 4.5 Key takeaways
- 4.6 Market drivers and constraints
- 4.7 Drug-class specific trends
- 4.8 Country-specific trends
- 5. Competitive Landscape
- 5.1 Current therapies
- 5.1.1 Key takeaways
- 5.1.2 Dx and Tx journey/algorithm
- 5.1.3 Key current therapies – profiles and KOL insights
- 5.2 Emerging therapies
- 5.2.1 Key takeaways
- 5.2.2 Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- 5.2.3 Notable early-phase pipeline
- 6. Unmet Need and TPP Analysis
- 6.1 Top unmet needs and future attainment by emerging therapies
- 6.2 TPP analysis and KOL expectations
- 7. Regulatory and Reimbursement Environments (by country and payer insights)
- 8. Appendix (e.g., bibliography, methodology)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
